Agents and Actions

, Volume 27, Issue 3–4, pp 351–355 | Cite as

Pharmacological comparison of active and passive experimental allergic encephalomyelitis in the rat

  • S. Desai
  • R. Barton
Animal Models

Abstract

Models of actively induced and passively transferred experimental allergic encephalomyelitis (EAE) have been compared in the rat. The time of disease onset, severity of clinical symptoms and percent incidence were compared and assessed for their suitability for evaluation of immunosuppressive agents. The passive EAE model had an earlier disease onset (6±0.1 days) and 100% of the cell recipients (n=45) developed severe clinical symptoms, including paralysis of the tail and hind limbs. In contrast, the active EAE model had a mean disease onset day of 13±0.1 and only 53% of the induced rats (n=85) developed EAE clinical symptoms which were variable. The average symptom score in both models was inhibited by dexamethasone (1 mg/kg/day p.o.; day 0 to 3), methotrexate (3 mg/kg i.p. single dose; day 1) and cyclosporin A (30 mg/kg/day p.o.; day 0 to 7). The above study indicates that the passive EAE model is more advantageous for pharmacologic evaluation of immunosuppressive agents.

Keywords

Dexamethasone Methotrexate Clinical Symptom Cyclosporin Disease Onset 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    M. W. Kies,Experimental allergic encephalomyelits in biology of brain dysfunction. (Ed. G. E. Gaull) pp. 185–224, Plenum Press, New York 1973.Google Scholar
  2. [2]
    P. Y. Paterson,Autoimmune diseases of myelin. Prog. Clin. Biol. Res.49, 19–36 (1980).Google Scholar
  3. [3]
    A. Ben-Nun, Y. Ron, and I. R. Cohen,Spontaneous remission of autoimmune encephalomyelitis is inhibited by splenectomy, thymectomy or ageing. Nature (Lond)288, 389–390 (1981a).Google Scholar
  4. [4]
    D. J. Hinrichs, C. M. Roberts, and F. J. Waxman,Regulation of paralytic experimental allergic encephalomyelitis in rats: susceptibility to active and passive disease reinduction. J. Immunol.126, 1857–1862 (1981).Google Scholar
  5. [5]
    H. S. Panitch, and D. E. McFarlin,Experimental allergic encephalomyelitis: enhancement of cell-mediated transfer by concanavalin A. J. Immunol.119, 1134–1137 (1977).Google Scholar
  6. [6]
    M. E. Westarp, H. Wekerle, A. Ben-Nun, I. R. Cohen, M. L. Vohl and H. Przuntek,T lymphocyte line-mediated experimental allergic encephalomyelitis — a pharmacologic model for testing of immunosuppressive agents for the treatment of autoimmune central nervous system disease. J. Pharmacol. Exp. Ther.242, 614–620 (1987).Google Scholar
  7. [7]
    D. J. Hinrichs, K. W. Wegmann, and B. A. Peters,The influence of cyclosporin A on the development of actively induced and passively transferred experimental allergic encephalomyelitis. Cell. Immunol.77, 202–209 (1983).Google Scholar
  8. [8]
    S. Levine, R. Sowinski, and S. L. Abreu,Suppression of experimental allergic encephalomyelitis by tilorone: cell transfer and interferon studies. Immunopharmacol.6, 23–30 (1983).Google Scholar

Copyright information

© Birkhäuser Verlag 1989

Authors and Affiliations

  • S. Desai
    • 1
  • R. Barton
    • 1
  1. 1.Departments of Pharmacology and ImmunologyBoehringer Ingelheim Pharmaceuticals Inc.RidgefieldUSA

Personalised recommendations